Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03935958

Curcumin in Kidney Transplant Recipients

The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Illinois at Chicago

Chicago, Illinois, 60612, United States

About this study

Kidney transplant recipients are at increased risk of death from cardiovascular disease (CVD). Inflammation, oxidative stress and vascular dysfunction (impaired endothelial function and increased large elastic artery stiffness), are highly prevalent in kidney transplant recipients and contribute to the high incidence of CVD in this patient population. The most common cause of kidney transplant failure is interstitial fibrosis and tubular atrophy (IFTA). The incidence of IFTA is as high as 50% of kidney transplants at 1 year after transplantation. The pathophysiology of IFTA is not well understood. Possible mechanisms include chronic rejection or injury, inflammation, and drug toxicity. Kidney transplant recipients suffer from high rates of cognitive decline for which the investigators lack effective therapies. Thus, therapeutic interventions targeting inflammation, oxidative stress, vascular dysfunction, and cognitive impairment are a priority.

Curcumin may have positive effects in terms of cardiovascular and nephroprotection because of its antibacterial, antiviral, anti-inflammatory and anti-oxidative effects. The aim of this study is to elucidate the role of curcumin as a nutritional strategy to reduce cardiovascular risk factors as well as inflammation and oxidative stress in kidney transplant recipients. The study aims to examine if curcumin will improve endothelial function by reducing markers of inflammation and oxidative stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive function in kidney transplant recipients.

Curcumin is a natural polyphenol with anti-inflammatory and antioxidant characteristics. Preliminary data indicate that curcumin administration improves endothelial dysfunction by reducing oxidative stress and inflammation and may improve cognitive function.

The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.

Objectives:

  • Evaluate the effects of curcumin on kidney transplant graft function
  • Evaluate the effects of curcumin supplementation on cognitive function.
  • Evaluate the effects of curcumin on diabetes and cardiovascular outcomes
  • Evaluate the effects of curcumin on systemic and endothelial cell markers of inflammation and oxidative stress.

Methods:

Patients will be randomized 1:1 to receive either curcumin or placebo starting at the time of transplant or up to 2 weeks prior to transplant. Patients will be followed per standard of care for kidney transplant recipients. Additional blood (30mL) and urine samples will be drawn prior to transplant and at 3, 6 and 12 months post-transplant to be used for future analysis. There will be a total of 4 visits for this study. Additionally, two questionnaires will be distributed at each visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject is a recipient of a living donor or deceased donor kidney only transplant
  • The subject is > 18 years of age

Exclusion criteria

  • The subject has had a multi-organ transplant
  • Subjects that were taking curcumin pre-transplant

Treatment and study plan

Curcumin

Dietary Supplement

Patients will receive curcumin 2000 mg a day, for 12 months

Other names: Longvida

Placebo

Other

Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months

Other names: Longvida

Primary outcomes

  1. Graft Outcomes

    Time frame: 12 months

    Change in GFR at 3, 6 and 12 months

  2. Cognitive function & Pain

    Time frame: 12 months

    Change in Neuro-QOL Item Bank v2.0 at 0, 3, 6, and 12 months

  3. Graft Outcomes

    Time frame: 12 months

    Difference in biopsy scores at 3 and 12 months

  4. Cognitive function & Pain

    Time frame: 12 months

    Global Pain Scale at 0, 3, 6, and 12 months

  5. Inflammation and oxidative stress

    Time frame: 12 months

    Markers of inflammation and oxidative stress at 0,3,6, & 12 months

Sponsors and collaborators

Lead sponsor

University of Illinois at Chicago

Other

Collaborators

  • Verdure Sciences

Registry information

Official study title

A Pilot 12 Month, Randomized, Controlled Trial of Curcumin in Kidney Transplant Recipients

Important dates

Study start
2019
Primary completion
2023
Study completion
2027
First posted
May 2, 2019
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.